SignPath Pharma Inc

SignPath Pharma Inc. is a clinical stage biotechnology company headquartered in Sandy, Utah. Founded in 2006, the company operates as a Delaware corporation. SignPath Pharma employs four individuals and generates approximately $2.5 million in annual revenue. SignPath Pharma focuses on developing innovative products targeting various medical challenges. Their current research efforts concentrate on treatments for cancer, mitigation of drug-induced cardiac arrhythmia, a common and potentially dangerous side effect of numerous medications, and heart muscle damage often caused by chemotherapy. SignPath Pharma distinguishes itself through its commitment to addressing critical medical needs, particularly in the areas of cancer treatment and managing the adverse effects associated with various pharmaceuticals. Their research aims to improve patient outcomes by developing effective therapies for these challenging conditions. Visit SignPath Pharma's website at www.signpathpharma.com for more information.